Fig. 6.

SR9009 application for 7 consecutive days attenuated astrocyte activation in the pilocarpine-induced SE model. a GFAP immunofluorescence staining in the CA1 and CA3 regions of the hippocampus in vehicle-treated control mice, SR9009-treated control mice, vehicle-treated pilocarpine mice, and SR9009-treated pilocarpine mice. b, c The level of GFAP-positive cells in the CA1 and CA3 regions was decreased in SR9009-treated pilocarpine mice compared to the vehicle-treated pilocarpine mice. d Western blotting analysis showed that SR9009 significantly reduced the protein level of GFAP in the hippocampus after SE. n = 3 for each group. The data presented as the mean ± SD. NS, not significant, *p < 0.05, **p < 0.01, ^†p < 0.001. Scale bar = 50 μm